Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 8/20 | 0.72 |
| ▸ | KCNK9 | Q9NPC2 | 7/20 | 0.72 |
| ▸ | HPGD | P15428 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.64 |
| ▸ | DHX9 | Q08211 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 4/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.63 |
| ▸ | POLB | P06746 | 2/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27681315 | 1.00 | KCNK3 (0.72) | KCNK3KCNK9HPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL25368211 | 0.91 | HPGD (0.65) | KCNK3KCNK9HPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL30543903 | 0.91 | HPGD (0.65) | KCNK3KCNK9HPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL30543923 | 0.90 | F2R (0.63) | KCNK3KCNK9HPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL25368621 | 0.90 | F2R (0.63) | KCNK3KCNK9HPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL27982693 | 0.85 | MEN1 (0.69) | HPGDALDH1A1SMN1; SMN2SIRT1MEN1 | |
| SCHEMBL2298254 | 0.85 | KCNK3 (1.00) | KCNK3KCNK9HPGDALDH1A1SIRT1 | |
| SCHEMBL12052345 | 0.84 | HPGD (0.60) | KCNK3KCNK9HPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL19329644 | 0.83 | ALDH1A1 (0.65) | KCNK3KCNK9HPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL31610012 | 0.83 | HPGD (0.53) | KCNK3KCNK9HPGDALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179013-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. | 2025-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179013-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | DHX9, DHX29, DDX39B | KCNK3 3925/4885KCNK9 2279/4885HPGD 852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.